Memantine and Fall Risk in Clinical Trial Evidence

Guideline Review Findings

• The 2008 guideline review (Annals of Internal Medicine) indicated that, in randomized trials of cholinesterase inhibitors for dementia, fall rates were marginally higher in some treatment arms, whereas memantine‑treated participants did not experience a statistically significant increase in falls compared with placebo, reflecting high‑certainty evidence that memantine does not raise fall risk in controlled trial populations. 1